Sanofi $SNY Holdings Decreased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 2.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 94,856 shares of the company’s stock after selling 2,186 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Sanofi were worth $4,582,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SNY. Ameritas Advisory Services LLC purchased a new position in Sanofi in the second quarter valued at about $28,000. Accent Capital Management LLC purchased a new position in Sanofi in the first quarter valued at about $29,000. Eastern Bank grew its stake in Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA purchased a new position in Sanofi in the first quarter valued at about $33,000. Finally, Golden State Wealth Management LLC grew its stake in Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

NASDAQ SNY opened at $48.80 on Tuesday. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The stock has a market capitalization of $119.83 billion, a PE ratio of 11.73, a P/E/G ratio of 1.17 and a beta of 0.51. The stock has a 50-day simple moving average of $48.29 and a 200 day simple moving average of $49.70.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same period in the prior year, the firm posted $1.73 EPS. Sanofi’s revenue for the quarter was down 7.0% on a year-over-year basis. Research analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on SNY shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Barclays reiterated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Finally, Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.